The Effects of One Month Consumption of Standardized Aronia Melanocarpa Extract on Anemia in Patients on Hemodialysis

December 21, 2019 updated by: Isidora Milosavljevic, University of Kragujevac

The Effects of One Month Consumption of Standardized Aronia Melanocarpa Extract on Anemia in Patients on Hemodialysis: Focus on Oxidative Stress and Inflammation

In this study are included patients on hemodialysis with anemia (levels of Hemoglobin<110). After baseline measurements tha patients take Standardized Aronia melanocarpa extract for one mont and then all measurements were repeated.

Study Overview

Status

Terminated

Detailed Description

  1. Patients The study included 30 patients with chronic kidney failure on dialysis treatment at the Center for Nephrology and Dialysis of the Clinical Center Kragujevac. Inclusion criteria were: regular dialysis treatment for more than 3 months, 3 times a week and hemoglobin values lower than 110g / L. Exclusion criteria were: hemoglobin values lower than 80g/L, the use of antioxidant and immunosuppressive therapy, uncontrolled malignancies, proven active bleeding and presence of systemic inflammation or active infection.
  2. Ethical approval The research was conducted with respect to the Helsinki Declaration on Medical Research, the approval of the Ethics Committee of the Clinical Center Kragujevac No 01-14-3039. All subjects provided written informed consent before study enrollment.
  3. Used plant extract Standardized Aronia extract (SAE) is official product of pharmaceutical company Pharmanova (Belgrade, Serbia); nevertheless, procedure of extraction was done by EU-Chem company (Belgrade, Serbia). This product contains 400mg/30ml of polyphenols, while the recommended daily dosage is 30ml.
  4. Blood sampling Patients included in the study consumed standardized Aronia melanocarpa extract (30ml/day) for 30 days. On the day 0, before SAE consumption, blood samples from all patients were collected for hematologic analyzes, inflammation parameters, oxidative stress parameters and antioxidant protection before the dialysis procedure. All mentioned parameters were determined again after consuming the product, ie. on the 30th day of the study.
  5. Analytic Procedures Venous blood samples (2 x 4.5ml) were taken before the start of supplementation (zero day) and at the end of supplementation (30th day). Vacuum tubes with sodium citrate were used for blood sampling. The first sample was used for routine hematologic analyzes, the second sample was used for plasma and erythrocyte lysate extraction in order to determinate redox and inflammatory status.
  6. Evaluation of Systemic Redox State Plasma samples were used for determination of the levels of the following pro-oxidants: superoxide anion radical (O2-), hydrogen peroxide (H2O2), nitrites (NO2-) and index of lipid peroxidation measured as thiobarbituric acid reactive substances (TBARS), while the parameters of antioxidative defence system, such as activities of superoxide dismutase (SOD) and catalase (CAT) and level of reduced glutathione (GSH) were determined in erythrocytes lysates samples.

    A) Index of lipid peroxidation (TBARS) determination The degree of lipid peroxidation in the plasma samples was estimated by measuring TBARS, using 1% thiobarbituric acid in 0.05 NaOH, which was incubated with the sample at 100°C for 15 min and measured at 530 nm. TBA extract was obtained by combining 0.8 ml sample and 0.4 ml trichloro acetic acid (TCA); afterwards, the samples were put on ice for 10 min and centrifuged for 15 min at 6000 rpm. (1).

    b) Nitrite determination (NO2-)

    Nitric oxide (NO) decomposes rapidly to form stable nitrite/nitrate products. The NO2- level was measured and used as an index of NO production, using Griess's reagent. For NO2 - determination in plasma 0.1 ml 3 N PCA (perchloride acid), 0.4 ml 20 mM ethylenediaminetetraacetic acid (EDTA) and 0.2 ml plasma were put on ice for 15 min, then centrifuged for 15 min at 6000 rpm. After pouring off the supernatant, 220 μl K2CO3 was added. Nitrites were measured at 550 nm. (2)

    1. Superoxide anion radical determination (O2-)

      Superoxide anion radical concentrations in plasma samples were measured using the NTB (Nitro Blue Tetrazolium) reagent in TRIS buffer (assay mixture). The measurement was performed at a wavelength of 530 nm. (3).

    2. Hydrogen peroxide determination (H2O2)

      The measurement of H2O2 was based on the oxidation of phenol red by H2O2 in a reaction catalyzed by horseradish peroxidase. Two hundred microlitres of perfusate or plasma was precipitated using 800 mL of freshly prepared phenol red solution; 10 μL of (1:20) horseradish peroxidase (made immediately before use) was subsequently added. The level of H2O2 was measured at 610 nm (4).

    3. Determination of reduced glutathione (GSH)

      The level of reduced glutathione (GSH) was determined based on GSH oxidation via 5,5-dithiobis-6,2-nitrobenzoic acid. GSH extract was obtained by combining 0.1 ml 0.1% EDTA, 400 μl hemolysate, and 750 μl precipitation solution (containing 1.67 g metaphosphoric acid, 0.2 g EDTA, 30 g NaCl, and filled with distilled water until 100 ml; the solution is stable for 3 weeks at +4C°). The level of GSH was measured at 420 nm (5).

    4. Determination of antioxidant enzymes (SOD, CAT)

    Isolated RBCs were washed three times with three volumes of ice-cold 0.9 mmol/l NaCl, and hemolysates containing about 50 g Hb/l were used for the determination of CAT activity. CAT buffer, prepared hemolysate sample, and 10 mM H2O2 were used for CAT determination. Detection was performed at 360 nm. SOD activity was determined by the epinephrine method. Hemolysate was mixed with carbonate buffer, and then epinephrine was added. Detection was performed at 470 nm (6-10).

  7. Evaluation of the inflammatory status In order to evaluate the inflammatory status of patients, following parameters were measured at both points of interest (0 and 30th day): serum C-reactive protein concentration - CRP and tumor necrosis factor concentration - TNF-α.

    The serum C- reactive protein (CRP) concentration was determined by the turbidimetric method on the Olympus AU680. The normal serum CRP concentration is ≤ 5 mg/L. Microinflammation is defined as the concentration of CRP in the serum of 5 mg/L.

    Plasma TNF-α concentrations were determined by enzyme linked immunoadsorbent assay (ELISA) using commercially available high sensitivity indirect sandwich enzyme-linked immunosorbent assay (Sigma Aldrich).

  8. Evaluation of the hematological parameters

    At both points of interest, the values of the following haematological parameters in all patients were analyzed:

    Erythrocytes (Er), hemoglobin (Hb), hematocrit (Hct), erythrocyte index- mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), serum lactate dehydrogenase concentration (LDH), serum haptoglobin concentration and iron status: serum iron concentration, ferritin; total iron binding capacity (TIBC), unsaturated iron binding capacity (UIBC), transferrin saturation (TSAT), haptoglobin.

  9. Statistical Analysis IBM SPSS Statistics 20.0 Desktop for Windows was used for statistical analysis. Shapiro-Wilk test was used to check the distribution of data. Statistical comparisons were performed using the one-way analysis of variance (ANOVA) tests with a Tukey's post hoc test for multiple comparisons, in the case of normal distribution of data between groups, while Kruskal-Wallis was used for comparison between groups where the distribution of data was different than normal. Values of p < 0.05 were considered to be statistically significant.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kragujevac, Serbia, 34000
        • Faculty of Medical Science

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

37 years to 68 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • regular dialysis treatment for more than 3 months, 3 times a week
  • hemoglobin values lower than 110g / L

Exclusion Criteria:

  • hemoglobin values lower than 80g/L,
  • the use of antioxidant and immunosuppressive therapy,
  • uncontrolled malignancies,
  • proven active bleeding
  • presence of systemic inflammation or active infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental group
Patients on hemodialysis who consumed one month Standardized Aronia Melanocrpa extract
During 30 days all patients take every day 30ml of Alixir 400 protect

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anemia control
Time Frame: two months
The iron levels Unit µmol/l
two months
Anemia control
Time Frame: two months
The hemoglobin levels Unit g/l
two months
Anemia control
Time Frame: two months
The ferritin levels Unit ng/ml
two months
Anemia control
Time Frame: two months
The transferrin levels Unit g/l
two months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxidative stress
Time Frame: two months
Superoxide anion radical, Hydrogen peroxide, Nitrites Units nmol/ml
two months
Oxidative stress
Time Frame: two months
Superoxide dismutase, Catalase Units U/g Hb x 1000
two months
Oxidative stress
Time Frame: two months
Reduced glutathione Unit nmol/l RBC x 1000
two months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inflammation
Time Frame: two months
The parameters of inflammation CRP Unit mg/l
two months
Inflammation
Time Frame: two months
The parameters of inflammation TNF alpha Unit pg/ml
two months
Inflammation
Time Frame: two months
The parameters of inflammation white blood cells Unit x 1000000000 cells/l
two months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Isidora Milosavljevic, Department of pharmacy, University of Kragujevac

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2019

Primary Completion (Actual)

October 1, 2019

Study Completion (Actual)

October 1, 2019

Study Registration Dates

First Submitted

December 18, 2019

First Submitted That Met QC Criteria

December 20, 2019

First Posted (Actual)

December 23, 2019

Study Record Updates

Last Update Posted (Actual)

December 24, 2019

Last Update Submitted That Met QC Criteria

December 21, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Alixir400protect

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anemia

Clinical Trials on Alixir 400 Protect

3
Subscribe